Trial Profile

A Phase 3, Multicenter, Randomized, Efficacy Assessor-Blinded Study of Risankizumab Compared to Ustekinumab for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease Who Have Failed Anti-TNF Therapy

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 29 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Risankizumab (Primary) ; Risankizumab (Primary) ; Ustekinumab; Ustekinumab; Vedolizumab
Indications Crohn's disease
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms SEQUENCE
Sponsors AbbVie

12 Aug 2025 Planned End Date changed from 15 Feb 2028 to 1 Feb 2028.
12 Aug 2025 Planned primary completion date changed from 15 Feb 2028 to 1 Feb 2028.
17 Jun 2024 Planned End Date changed from 11 Feb 2028 to 15 Feb 2028.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com